Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery, dyspnea 89% Improvement Relative Risk Recovery, anosmia 95% Recovery, fatigue 94% Recovery, myalgia -388% Recovery, headache -194% Recovery, cough 9% c19early.org/z Kumar et al. CTRI/2021/06/034254 Zinc RCT EARLY TREATMENT Is early treatment with zinc+combined treatments beneficial for COVID-19? RCT 192 patients in India (December 2021 - February 2022) Improved recovery with zinc+combined treatments (not stat. sig., p=0.053) Kumar et al., Cureus, doi:10.7759/cureus.25467 Favors zinc Favors control
Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to Moderate COVID-19 Patients: A Randomized Controlled Clinical Trial
Kumar et al., Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to.., Cureus, doi:10.7759/cureus.25467, CTRI/2021/06/034254
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 260 patients in India, 130 treated with aspirin, promethazine, vitamin C, D, B3, zinc, and selenium, showing faster recovery with treatment. There was no hospitalization, ICU admission, or supplemental oxygen requirements in either group.
risk of no recovery, 89.2% lower, RR 0.11, p = 0.05, treatment 0 of 99 (0.0%), control 4 of 93 (4.3%), NNT 23, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 10, dyspnea.
risk of no recovery, 95.4% lower, RR 0.05, p < 0.001, treatment 0 of 99 (0.0%), control 10 of 93 (10.8%), NNT 9.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 10, anosmia.
risk of no recovery, 94.3% lower, RR 0.06, p = 0.003, treatment 0 of 99 (0.0%), control 8 of 93 (8.6%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 10, fatigue.
risk of no recovery, 387.9% higher, RR 4.88, p = 0.50, treatment 2 of 99 (2.0%), control 0 of 93 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 10, myalgia.
risk of no recovery, 193.9% higher, RR 2.94, p = 1.00, treatment 1 of 99 (1.0%), control 0 of 93 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 10, headache.
risk of no recovery, 8.5% lower, RR 0.91, p = 0.66, treatment 37 of 99 (37.4%), control 38 of 93 (40.9%), NNT 29, day 10, cough.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kumar et al., 30 May 2022, Randomized Controlled Trial, India, peer-reviewed, mean age 36.0, 8 authors, study period December 2021 - February 2022, this trial uses multiple treatments in the treatment arm (combined with aspirin, promethazine, vitamin C, D, B3, and selenium) - results of individual treatments may vary, trial CTRI/2021/06/034254.
Contact: vgvclinical@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: Open Access Original Article DOI: 10.7759/cureus.25467 Efficacy and Safety of Aspirin, Promethazine, and Micronutrients for Rapid Clinical Recovery in Mild to Moderate COVID-19 Patients: A Randomized Controlled Clinical Trial Review began 05/12/2022 Review ended 05/20/2022 Published 05/30/2022 © Copyright 2022 Kumar et al. This is an open access article distributed under the terms of the Creative Dr. G. Sunil Kumar 1 , Dr.Atul Vadgaonkar 2 , Dr. Srilata Purunaik 3 , Rohit Shelatkar 4 , Vidyadhar G. Vaidya Sr. 5 , Dr. Gayatri Ganu 6 , Dr. Aditya Vadgaonkar 7 , Shashank Joshi 8 Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 1. Cardiology, S K Clinic & Scans, Thiruvanathapuram, IND 2. General Medicine, Vijay Nursing Home, Nashik, IND 3. Respiratory Medicine, Swasthi Orthopaedic and Respiratory Health Care, Bengaluru, IND 4. Pharmacology and Therapeutics, Vitabiotics Ltd., London, GBR 5. General Surgery, Lokmanya Medical Research Centre, Pune, IND 6. Pharmacology and Therapeutics, Mprex Healthcare Pvt. Ltd., Pune, IND 7. Medicine, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, IND 8. Endocrinology, Lilavati Hospital, Mumbai, IND Corresponding author: Vidyadhar G. Vaidya Sr., vgvclinical@gmail.com Abstract
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit